London has recorded its lowest IPO volume in the first half-year since 1997, prompting concerns about the viability of its trading venue. A significant amount, over $100 billion, in London-listed companies are planning to move to the US for better liquidity conditions. AstraZeneca’s CEO, Pascal Soriot, is contemplating a stock listing transition due to regulatory frustrations. The ongoing trend of UK companies receiving takeover offers further hinders London’s IPO prospects, with 48 such deals already initiated this year.
London's IPO volume is at its slowest half-year since 1997, highlighting a significant concern regarding its market appeal alongside a potential AstraZeneca US listing.
More than $100 billion in London-listed companies have planned moves to New York, indicating a clear shift towards markets with greater liquidity and regulatory support.
Pascal Soriot, Bayer's CEO, expresses frustration with UK's regulations and fears that the UK life sciences sector might fall behind the US and China, pushing AstraZeneca to consider a US listing.
UK-listed companies are facing an influx of takeover offers in 2023, with 48 deals already completed or pending, which could further deplete the London exchange.
Collection
[
|
...
]